Matthew Kurian, Assistant Professor of Medicine at the University of Kentucky College of Medicine and Physician at St. Elizabeth Healthcare, shared a post on LinkedIn:
“Breakthrough HER2 Vaccine Update!
The experimental breast cancer vaccine GLSI-100 just earned FDA Fast Track status —a big step toward earlier approval.
How it works:
GP2 peptide (from HER2) + GM-CSF → trains the immune system to recognize HER2 and attack any leftover cancer cells after treatment.
The FLAMINGO-01 trial is testing GLSI-100 to help prevent HER2-positive breast cancer recurrence.
(Details: ClinicalTrials.gov)
Dosing Schedule
Intradermal injections every month for the first 6 months, then every 6 months for the next 2.5 years— for a total of 11 intradermal injections over 3 years
Eligible Participants
- Stage I–III – Residual invasive cancer in the breast or lymph nodes after neoadjuvant therapy OR
- Stage III -Complete pathologic response after neoadjuvant therapy
- Genetics: HLA-A*02 positive (separate arm available for HLA-A*02-negative)
- Treatment: Completed both neoadjuvant & adjuvant trastuzumab-based therapy
- Timing: Able to start the vaccine within 1 year of completing adjuvant trastuzumab-based therapy (can still be on endocrine therapy if eligible).
Don’t miss Dr. Eleonora Teplinsky, MD, FASCO’s fantastic breakdown of the science and data
Watch on Instagram!”
More posts featuring Matthew Kurian.